Alicia Grande net worth and biography

Alicia Grande Biography and Net Worth

Alicia Grande, CPA, CMA, was appointed Vice President, Chief Financial Officer and Treasurer of Catalyst in December 2011, having joined the company as Corporate Controller and Chief Accounting Officer in 2007. Prior to that, she was Senior Director of Finance for The Hackett Group, Inc. (then known as Answerthink, Inc.), where she was responsible for all external and SEC financial reporting and served as head of the firm’s Sarbanes-Oxley Act compliance team. Ms. Grande previously was employed for more than 10 years by various public accounting firms, including Arthur Andersen, LLP. Ms. Grande earned a bachelor of science degree in business administration, with majors in accounting and finance, from Syracuse University and a master of accounting degree from Florida International University.

What is Alicia Grande's net worth?

The estimated net worth of Alicia Grande is at least $460,751.18 as of November 22nd, 2022. Ms. Grande owns 27,442 shares of Catalyst Pharmaceuticals stock worth more than $460,751 as of December 6th. This net worth approximation does not reflect any other assets that Ms. Grande may own. Additionally, Ms. Grande receives an annual salary of $617,940.00 as CFO at Catalyst Pharmaceuticals. Learn More about Alicia Grande's net worth.

How old is Alicia Grande?

Ms. Grande is currently 51 years old. There are 6 older executives and no younger executives at Catalyst Pharmaceuticals. The oldest executive at Catalyst Pharmaceuticals is Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO, who is 75 years old. Learn More on Alicia Grande's age.

What is Alicia Grande's salary?

As the CFO of Catalyst Pharmaceuticals, Inc., Ms. Grande earns $617,940.00 per year. There are 3 executives that earn more than Ms. Grande. The highest earning executive at Catalyst Pharmaceuticals is Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO, who commands a salary of $1,050,000.00 per year. Learn More on Alicia Grande's salary.

How do I contact Alicia Grande?

The corporate mailing address for Ms. Grande and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected] Learn More on Alicia Grande's contact information.

Has Alicia Grande been buying or selling shares of Catalyst Pharmaceuticals?

In the last ninety days, Alicia Grande has sold $2,929,800.00 in Catalyst Pharmaceuticals stock. Most recently, Alicia Grande sold 120,000 shares of the business's stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $16.53, for a transaction totalling $1,983,600.00. Following the completion of the sale, the chief financial officer now directly owns 27,442 shares of the company's stock, valued at $453,616.26. Learn More on Alicia Grande's trading history.

Who are Catalyst Pharmaceuticals' active insiders?

Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Alicia Grande (CFO), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), and Steven Miller (COO & Chief Scientific Officer ). Learn More on Catalyst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Catalyst Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 24 times. They sold a total of 1,742,297 shares worth more than $26,268,304.10. The most recent insider tranaction occured on November, 23rd when COO Steve Miller sold 20,000 shares worth more than $346,800.00. Insiders at Catalyst Pharmaceuticals own 14.1 % of the company. Learn More about insider trades at Catalyst Pharmaceuticals.

Information on this page was last updated on 11/23/2022.

Alicia Grande Insider Trading History at Catalyst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2022Sell120,000$16.53$1,983,600.0027,442View SEC Filing Icon  
11/15/2022Sell60,000$15.77$946,200.00147,442View SEC Filing Icon  
9/23/2022Sell60,000$11.90$714,000.00207,442View SEC Filing Icon  
9/16/2022Sell90,000$13.50$1,215,000.00267,442View SEC Filing Icon  
9/14/2022Sell50,000$15.57$778,500.00357,442View SEC Filing Icon  
8/29/2022Sell57,000$14.20$809,400.00407,442View SEC Filing Icon  
8/26/2022Sell11,095$14.40$159,768.00464,442View SEC Filing Icon  
8/17/2022Sell130,741$13.86$1,812,070.26475,537View SEC Filing Icon  
8/17/2021Sell100,000$5.67$567,000.00507,441View SEC Filing Icon  
See Full Table

Alicia Grande Buying and Selling Activity at Catalyst Pharmaceuticals

This chart shows Alicia Grande's buying and selling at Catalyst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Read More

Today's Range

Now: $16.42
Low: $16.20
High: $17.00

50 Day Range

MA: $14.38
Low: $12.25
High: $17.51

2 Week Range

Now: $16.42
Low: $5.24
High: $18.39

Volume

96,712 shs

Average Volume

2,821,961 shs

Market Capitalization

$1.71 billion

P/E Ratio

26.92

Dividend Yield

N/A

Beta

1.25
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill.
While the left touts "all about the environment," why is the recent infrastructure bill shuffling PILES of money to this little-known mining industry?
HINT: It's Because Of A National Security Crisis